IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice - PubMed (original) (raw)
. 2003 Jan 1;170(1):270-8.
doi: 10.4049/jimmunol.170.1.270.
Paolo Serafini, Carmela De Santo, Ilaria Marigo, Valeria Tosello, Alessandra Mazzoni, David M Segal, Caroline Staib, Marianne Lowel, Gerd Sutter, Mario P Colombo, Paola Zanovello
Affiliations
- PMID: 12496409
- DOI: 10.4049/jimmunol.170.1.270
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice
Vincenzo Bronte et al. J Immunol. 2003.
Abstract
We previously demonstrated that a specialized subset of immature myeloid cells migrate to lymphoid organs as a result of tumor growth or immune stress, where they suppress B and T cell responses to Ags. Although NO was required for suppression of mitogen activation of T cells by myeloid suppressor cells (MSC), it was not required for suppression of allogenic responses. In this study, we describe a novel mechanism used by MSC to block T cell proliferation and CTL generation in response to alloantigen, which is mediated by the enzyme arginase 1 (Arg1). We show that Arg1 increases superoxide production in myeloid cells through a pathway that likely utilizes the reductase domain of inducible NO synthase (iNOS), and that superoxide is required for Arg1-dependent suppression of T cell function. Arg1 is induced by IL-4 in freshly isolated MSC or cloned MSC lines, and is therefore up-regulated by activated Th2, but not Th1, cells. In contrast, iNOS is induced by IFN-gamma and Th1 cells. Because Arg1 and iNOS share L-arginine as a common substrate, our results indicate that L-arginine metabolism in myeloid cells is a potential target for selective intervention in reversing myeloid-induced dysfunction in tumor-bearing hosts.
Similar articles
- Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection.
Brys L, Beschin A, Raes G, Ghassabeh GH, Noël W, Brandt J, Brombacher F, De Baetselier P. Brys L, et al. J Immunol. 2005 May 15;174(10):6095-104. doi: 10.4049/jimmunol.174.10.6095. J Immunol. 2005. PMID: 15879104 - Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells.
Liu Y, Van Ginderachter JA, Brys L, De Baetselier P, Raes G, Geldhof AB. Liu Y, et al. J Immunol. 2003 May 15;170(10):5064-74. doi: 10.4049/jimmunol.170.10.5064. J Immunol. 2003. PMID: 12734351 - L-arginine metabolism in myeloid cells controls T-lymphocyte functions.
Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. Bronte V, et al. Trends Immunol. 2003 Jun;24(6):302-6. doi: 10.1016/s1471-4906(03)00132-7. Trends Immunol. 2003. PMID: 12810105 Review. - Arginine availability, arginase, and the immune response.
Bansal V, Ochoa JB. Bansal V, et al. Curr Opin Clin Nutr Metab Care. 2003 Mar;6(2):223-8. doi: 10.1097/00075197-200303000-00012. Curr Opin Clin Nutr Metab Care. 2003. PMID: 12589193 Review.
Cited by
- Integrin receptor-targeted, doxorubicin-loaded cerium oxide nanoparticles delivery to combat glioblastoma.
Koula G, Yakati V, Rachamalla HK, Bhamidipati K, Kathirvel M, Banerjee R, Puvvada N. Koula G, et al. Nanomedicine (Lond). 2024 Jun 20;19(15):1389-1406. doi: 10.1080/17435889.2024.2350357. Epub 2024 Jun 24. Nanomedicine (Lond). 2024. PMID: 38912661 - A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.
Montoya M, Gallus M, Phyu S, Haegelin J, de Groot J, Okada H. Montoya M, et al. Cells. 2024 Apr 23;13(9):726. doi: 10.3390/cells13090726. Cells. 2024. PMID: 38727262 Free PMC article. Review. - Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion.
Lu J, Luo Y, Rao D, Wang T, Lei Z, Chen X, Zhang B, Li Y, Liu B, Xia L, Huang W. Lu J, et al. Exp Hematol Oncol. 2024 Apr 12;13(1):39. doi: 10.1186/s40164-024-00505-7. Exp Hematol Oncol. 2024. PMID: 38609997 Free PMC article. Review. - Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment.
Jou E, Chaudhury N, Nasim F. Jou E, et al. Explor Target Antitumor Ther. 2024;5(1):187-207. doi: 10.37349/etat.2024.00212. Epub 2024 Feb 28. Explor Target Antitumor Ther. 2024. PMID: 38464388 Free PMC article. Review. - Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells.
Glöckner HJ, Martinenaite E, Landkildehus Lisle T, Grauslund J, Ahmad S, Met Ö, Thor Straten P, Hald Andersen M. Glöckner HJ, et al. Oncoimmunology. 2024 Feb 22;13(1):2318053. doi: 10.1080/2162402X.2024.2318053. eCollection 2024. Oncoimmunology. 2024. PMID: 38404966 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous